Fig. 3From: Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patientsA Proportion of patients with presence of intraretinal fluid from baseline visit to week 48 visit. B Proportion of patients with presence of subretinal fluid from baseline visit to week 48 visit. C Proportion of patients with presence of subretinal hyperreflective material from baseline visit to week 48 visitBack to article page